Ratings for Ocular Therapeutix (NASDAQ:OCUL) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
1
0
0
Last 30D
1
0
0
0
0
1M Ago
0
0
0
0
0
2M Ago
2
2
1
0
0
3M Ago
0
0
0
0
0
The 12-month price targets, analyzed by analysts, offer insights with an average target of $16.17, a high estimate of $24.00, and a low estimate of $7.00. A 0.49% drop is evident in the current average compared to the previous average price target of $16.25.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of Ocular Therapeutix among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Yi Chen
HC Wainwright & Co.
Maintains
Buy
$14.00
$14.00
Yi Chen
HC Wainwright & Co.
Lowers
Buy
$14.00
$16.00
Jonathan Wolleben
JMP Securities
Lowers
Market Outperform
$22.00
$24.00
Tara Bancroft
TD Cowen
Lowers
Hold
$7.00
$11.00
Yi Chen
HC Wainwright & Co.
Maintains
Buy
$16.00
-
Jonathan Wolleben
JMP Securities
Maintains
Market Outperform
$24.00
-
Key Insights:
Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it ...Full story available on Benzinga.com
Benzinga
